bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Business Wire•08/10/2026•12:07 ET
8
Key Highlights
- ➤Approximately $4 million gross proceeds targeted through registered direct financing and private placement
- ➤Common stock priced at $6.122 per share; pre-funded warrants priced at $6.115
- ➤Private placement includes warrants for up to 980,072 shares at $6.122 exercise price
- ➤Net proceeds earmarked for working capital, CyPath® Lung sales support, and general corporate purposes
- ➤Offering closing expected on or about October 9, 2026, subject to customary conditions
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has entered into a definitive agreement with an institutional investor to sell shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $6.122 (or $6.115 per pre-funded warrant), in a registered direct offering priced at-the-market under Nasdaq rules.
Get started
Create a free account to read the full story.